SLC5A2 and chronic kidney disease: Prescribers may, however, be concerned that patient populations in clinical trials of SGLT2 inhibitors were not representative of patients aged >65 years (in the CREDENCE, DAPA-CKD, and EMPA-KIDNEY trials, the mean age of patients treated with SGLT2 inhibitors was 63 years, 62 years, and 64 years, respectively).3